Related Experiment Video
Updated: May 25, 2025
07:51
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
7.5K
Key Updates to the 2024 ESC Hypertension Guidelines and Future Perspectives
Alexandru Burlacu1,2, Masanari Kuwabara3,4, Crischentian Brinza1
1Faculty of Medicine, University of Medicine and Pharmacy "Grigore T Popa", 700115 Iasi, Romania.
Medicina (Kaunas, Lithuania)
|February 26, 2025
Summary
The 2024 ESC hypertension guidelines offer a comprehensive strategy for managing high blood pressure (hypertension), focusing on early detection, lifestyle changes, and personalized treatment to reduce cardiovascular risks.
Area of Science:
- Cardiology
- Public Health
Background:
- Hypertension is a major global health issue linked to cardiovascular disease.
- Current treatments face challenges in effective hypertension management.
Purpose of the Study:
- To outline the 2024 European Society of Cardiology (ESC) guidelines for hypertension management.
- To address gaps in current hypertension care through updated strategies.
Main Methods:
- Emphasizing comprehensive strategies: early detection, addressing socioeconomic factors, lifestyle interventions, and personalized care.
- Recommending enhanced screening (home and ambulatory monitoring) for accurate diagnosis.
- Updating lifestyle advice (sodium/potassium intake, exercise) and pharmacological approaches (single-pill combinations, strict BP targets).
Main Results:
- New guidelines promote accurate diagnosis and risk stratification through advanced monitoring.
- Updated recommendations include specific dietary and exercise plans.
- Pharmacological advancements include single-pill combinations and consideration of SGLT2 inhibitors.
- Exploration of minimally invasive therapies for resistant hypertension and digital tools for patient engagement.
Conclusions:
- The guidelines provide a patient-centered roadmap for optimizing blood pressure control.
- This approach aims to reduce cardiovascular risks in diverse populations.
- The guidelines emphasize a multifaceted strategy for tackling hypertension complexities.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
370
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
370
01:33Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
125
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
125
01:18Hypertension and Regulation of Blood Pressure
1.9K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: Diuretics
332
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
332